![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
More than a decade of intensive use of microarray technology has flooded the scientific community with genome-wide expression data of diverse biological states. As a result, connection of the expression signatures of a relatively small number of genes related to, for example, disease states, patient responses or toxicological responses has become possible. Development of tools that enable cost- and time-efficient analysis of such signatures from large sample numbers is currently of major interest for research, drug screening and diagnostic purposes. A method named transcript analysis with aid of affinity capture (TRAC) is a novel solution hybridization and bead-based assay enabling multiplex mRNA target detection simultaneously from large sample numbers. Functionality of TRAC has been shown in a number of applications, including microbial quantification, gene expression-based monitoring of biotechnical processes, cell-based cancer marker gene screening and siRNA validation, which are reviewed here.
Financial & competing interests disclosure
Jari Rautio is the head of R&D in VTT spin-off company PlexPress Oy (www.plexpress.fi), which is commercializing the Transcript analysis with aid of affinity capture (TRAC) technology. Both Jari Rautio and Hand Söderlund have stock ownership in PlexPress Oy. Hand Söderlund and Reetta Satokari have a granted patent related to TRAC technology.
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.